Literature DB >> 11777177

Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol.

R D Steigerwalt1, G Laurora, G V Belcaro, M R Cesarone, M T De Sanctis, L Incandela, R Minicucci.   

Abstract

The purpose of this study was to evaluate the effect of topical timolol 0.5%, betaxolol 0.5% and carteolol 2% on the blood flow velocity of the central retinal artery (CRA), the posterior ciliary artery (PCA) and the ophthalmic artery (OA) in patients with ocular hypertension. A group of 14 patients with ocular hypertension and a group of 11 normals were studied. The color Doppler was used to measure the peak systolic flow velocity (PSFV) and the end diastolic flow velocity (EDFV) of the CRA, the PCA and the OA in the normals and in the patients. The normals were under no treatment, while the patients were studied before and after treatment with topical timolol 0.5%, betaxolol 0.5% and carteolol 2%. In the systolic phase, there was a significant increase in the flow velocity of the CRA with all three drugs. In the diastolic phase of the CRA, the increase was significant for timolol 0.5% and carteolol 2% but not for betaxolol 0.5%. The flow velocity of the PCA and OA remained unchanged. In this study of 14 patients with ocular hypertension, topical timolol 0.5%, betaxolol 0.5% and carteolol 2% led to a significant increase in the flow velocity of the CRA without creating a steal or decrease in the flow velocity of the PCA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11777177     DOI: 10.1089/10807680152729220

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  4 in total

1.  The role of lipid dysregulation and vascular risk factors in glaucomatous retrobulbar circulation.

Authors:  Monika Modrzejewska; Wilhelm Grzesiak; Daniel Zaborski; Anna Modrzejewska
Journal:  Bosn J Basic Med Sci       Date:  2015-03-15       Impact factor: 3.363

2.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

3.  Mirtogenol potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects.

Authors:  Robert D Steigerwalt; Gianni Belcaro; Paolo Morazzoni; Ezio Bombardelli; Carolina Burki; Frank Schönlau
Journal:  Clin Ophthalmol       Date:  2010-05-14

4.  Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects.

Authors:  Robert D Steigerwalt; Belcaro Gianni; Morazzoni Paolo; Ezio Bombardelli; Carolina Burki; Frank Schönlau
Journal:  Mol Vis       Date:  2008-07-10       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.